Takeda Pharmaceutical Co.

Takeda Pharmaceutical Company Limited è la più grande casa farmaceutica del Giappone e la 12a per fatturato a livello mondiale. La società ha più di 30,000 dipendenti in tutto il mondo e ha fatturato oltre 18 miliardi di dollari nel 2012.
La società si focalizza su queste patologie: ulcera peptica, cancro alla prostata ed endometriosi, malattie urologiche, diabete e ipertensione, malattie respiratorie e infiammatorie, trattamento del dolore.
Takeda Pharmaceuticals è attiva anche nell'oncologia con una società indipendente,
Takeda ha 2 basi principali in Giappone a Osaka e Tokyo. La sua sede Americana si trova a Deerfield, Illinois, mentre quella Europea si trova a Zurigo, Svizzera.
I principali centri di ricerca si trovano a Osaka e Tsukuba, Giappone; San Diego, California; San Francisco, California; Cambridge, Regno Unito; e Singapore.
Gli stabilimenti produttivi sono 18 distribuiti in quattro continenti. (fonte: Wikipedia)
Comunicati Stampa

Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

-- No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study   (PR Newswire - 28/08/2014) Leggi

Takeda Receives Positive CHMP Opinions for Label Updates to Vipidia™ (alogliptin) and Fixed-Dose Combinations Vipdomet™ (alogliptin and metformin) and Incresync™ (alogliptin and pioglitazone)

"We're encouraged by the positive opinions for Vipidia, Vipdomet and Incresync as cardiovascular disease is the leading cause of morbidity and mortality in patients with Type 2 diabetes," said Elisabeth Genestin, MD, cardiometabolic medical affairs director, Europe & Canada, Takeda. "Having a robust data set demonstrating that alogliptin does not increase the risk of cardiovascular outcomes is important for the healthcare professionals who are treating people with Type 2 diabetes." (PR Newswire - 29/07/2014) Leggi

Endo completes acquisition of Grupo Farmaceutico Somar®

Additionally, Endo has appointed Norbert Oppitz as regional president, Latin America, Africa and Export Markets, effective October 1, 2014.  In this capacity, Mr. Oppitz will assume responsibility for Endo's business in Mexico, including Somar, as well as provide oversight for Endo's investment in Litha Healthcare, based in South Africa.  He brings to Endo a wealth of global pharmaceutical leadership experience and industry expertise, having overseen the growth and development of businesses for nearly 25 years in Latin America, the Middle East and North Africa.  Most recently, Mr. Oppitz held the leadership position of SVP Latin America for Takeda Pharmaceuticals. In his new role with Endo, Mr. Oppitz will report to Rajiv De Silva, Endo's president and chief executive officer. (PR Newswire - 24/07/2014) Leggi

Takeda Receives European Commission Marketing Authorisation for Entyvio(R) (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease

Vedolizumab is now approved for marketing in the 28 member states of the European Union as well as Norway, Iceland and Liechtenstein.   (PR Newswire - 27/05/2014) Leggi

Takeda Receives European Commission Marketing Authorisation for Entyvio® (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease

Vedolizumab is now approved for marketing in the 28 member states of the European Union as well as Norway, Iceland and Liechtenstein.   (PR Newswire - 27/05/2014) Leggi
1 2 3 4 5 6 7 8 9 10